Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycemic agents (MK-8835-062)

17/10/2019
11/02/2025
EU PAS number:
EUPAS31718
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

MK-8835-062-00-v4-Protocol_Final Redaction.pdf

English (3.92 MB - PDF) View document
Updated protocol

MK-8835-062-01-v1-Protocol_final redaction.pdf

First published: 07/02/2025
English (891.27 KB - PDF) View document
Study results
Study report
Study report

MK-8835-062-02-interim-report-dec-2022_final redaction

English (1.86 MB - PDF) View document

MK-8835-062-second-interim-report-nov-2022_final redaction

English (1.07 MB - PDF) View document

MK-8835-062-interim-report-dec-2021_final redaction.pdf

English (1.83 MB - PDF) View document

MK-8835-062-final-study-report-AUG-2024_final-redaction.pdf

English (1.25 MB - PDF) View document
Other information